These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16340026)

  • 1. Bone loss associated with long-term use of depot medroxyprogesterone acetate.
    Lo SS; Fan SY;
    Hong Kong Med J; 2005 Dec; 11(6):491-5. PubMed ID: 16340026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
    Cromer BA; Scholes D; Berenson A; Cundy T; Clark MK; Kaunitz AM;
    J Adolesc Health; 2006 Aug; 39(2):296-301. PubMed ID: 16857545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density and DMPA.
    Westhoff C
    J Reprod Med; 2002 Sep; 47(9 Suppl):795-9. PubMed ID: 12380409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
    Renner RM; Edelman AB; Kaunitz AM
    Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-acting contraceptives in adolescents.
    Tolaymat LL; Kaunitz AM
    Curr Opin Obstet Gynecol; 2007 Oct; 19(5):453-60. PubMed ID: 17885461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hormonal contraception on bone mineral density after 24 months of use.
    Berenson AB; Breitkopf CR; Grady JJ; Rickert VI; Thomas A
    Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depot medroxyprogesterone acetate (DMPA, Depo-Provera) in adolescents: what is next after the FDA black box warning.
    Omar H; Kives S
    J Pediatr Adolesc Gynecol; 2005 Jun; 18(3):183. PubMed ID: 15970252
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.
    Guilbert ER; Brown JP; Kaunitz AM; Wagner MS; Bérubé J; Charbonneau L; Francoeur D; Gilbert A; Gilbert F; Roy G; Senikas V; Jacob R; Morin R
    Contraception; 2009 Mar; 79(3):167-77. PubMed ID: 19185668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on hormonal contraception and bone density.
    Isley MM; Kaunitz AM
    Rev Endocr Metab Disord; 2011 Jun; 12(2):93-106. PubMed ID: 21559817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No bones about it--depot medroxyprogesterone acetate remains an excellent contraceptive option for adolescents.
    Rager KM
    J Pediatr Adolesc Gynecol; 2005 Jun; 18(3):187-8. PubMed ID: 15970254
    [No Abstract]   [Full Text] [Related]  

  • 12. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects.
    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
    Obstet Gynecol; 2008 Sep; 112(3):727-30. PubMed ID: 18757687
    [No Abstract]   [Full Text] [Related]  

  • 13. Nondaily hormonal contraception: establishing a fit between product characteristics and patient preferences.
    Levine JP
    J Fam Pract; 2004 Nov; 53(11):904-13. PubMed ID: 15527729
    [No Abstract]   [Full Text] [Related]  

  • 14. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians.
    Paschall S; Kaunitz AM
    Contraception; 2008 Nov; 78(5):370-6. PubMed ID: 18929733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis After Long-Term Depot Medroxyprogesterone: We Need More Data on Fracture Risk.
    Downs RW; Yazbeck CF
    J Womens Health (Larchmt); 2015 Aug; 24(8):619-20. PubMed ID: 26263280
    [No Abstract]   [Full Text] [Related]  

  • 16. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
    Kaunitz AM
    Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopsychosocial variables associated with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: adolescents who lost 5% or more from baseline vs. those who lost less than 5%.
    Harel Z; Wolter K; Gold MA; Cromer B; Stager M; Johnson CC; Brown R; Bruner A; Coupey S; Hertweck P; Bone H; Burkman R; Nelson A; Marshall S; Bachrach LK
    Contraception; 2010 Dec; 82(6):503-12. PubMed ID: 21074012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density in adolescent and young adult women on injectable or oral contraception.
    Cromer BA
    Curr Opin Obstet Gynecol; 2003 Oct; 15(5):353-7. PubMed ID: 14501237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate.
    Modesto W; Bahamondes MV; Bahamondes L
    J Womens Health (Larchmt); 2015 Aug; 24(8):636-40. PubMed ID: 26098552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density and depot medroxyprogesterone acetate.
    Albertazzi P; Bottazzi M; Steel SA
    Contraception; 2006 Jun; 73(6):577-83. PubMed ID: 16730487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.